000			03155cam a2200349 a 4500
003			EG-GiCUC
005			20250223031822.0
008			171009s2017 ua dh f m 000 0 eng d
040			_aEG-GiCUC _beng _cEG-GiCUC
041	0		_aeng
049			_aDeposite
097			_aPh.D
099			_aCai01.11.09.Ph.D.2017.Ab.I
100	0		_aAbdalla Youssef Fawzy Mohamed
245	1	4	_aThe Impact of biodegradable polymer drug eluting stents on the outcome of acute coronary syndrome / _cAbdalla Youssef Fawzy Mohamed ; Supervised Ahmed Abdelaziz , Ayman Moharam , Ibrahem Atia
246	1	5	_aتأثير الدعامات النشطة حيويا القابلة للتحلل على نتائج القسطرة التداخلية فى مرضى الأزمة القلبية الحادة
260			_aCairo : _bAbdalla Youssef Fawzy Mohamed , _c2017
300			_a116 P. : _bcharts , facsimiles ; _c25cm
502			_aThesis (Ph.D.) - Cairo University - Faculty of Medicine - Department of Critical Care Medicine
520			_aThe early benefit of early generation of drug eluting stent (DES) in terms of target lesion revascularization compared to bare metal stents was offset by increased incidence risk of late stent thrombosis. Newer generation biodegradable polymer DES was seen to improve vascular healing and clinical outcome. In this study we aim to assess of the role of biodegradable polymer DES in decreasing the incidence of major adverse cardiac events (MACE) after percutaneous coronary intervention (PCI) in comparison with durable polymer DES in patients with noníST-segment elevation acute coronary syndromes (NSTEACS). Methodology and Results This is a prospective, randomized study to compare between biodegradable polymer DES and durable DES. A total of 121 patients presenting to Critical Care Medicine Department, Cairo University with (NSTE-ACS). Participants were followed up clinically after 1-2 years. 52 of the patients with 69 lesions were allocated to treatment with BP DES and 69 patients with 86 lesions to treatment with DP DES. For overall incidence of in-hospital complications, comprising acute myocardial infarction, need for target lesion revascularization, urgent deferral to CABG and death there was no significant difference among different stents, (P 0.328). Also there was no significant differences among different stents in their 1-2 year follow up; seven patients were reported in 2follow-up MACCE3. Mortality was 1.7% (1 biodegradable DES & 1 durable polymer DES). (P 0.654) Five patients needed TLR (2 biodegrabale DES & 3 durable polymer DES). (P 0.632) Conclusions Biodegradable polymer and durable polymer DES are associated with similar clinical outcomes at 2 years.
530			_aIssued also as CD
653		4	_aAcute coronary syndrome
653		4	_aBiodegradable polymer drug
653		4	_aDrug eluting stent (DES)
700	0		_aAhmed Abdelaziz , _eSupervisor
700	0		_aAyman Moharam , _eSupervisor
700	0		_aIbrahem Atia , _eSupervisor
856			_uhttp://172.23.153.220/th.pdf
905			_aNazla _eRevisor
905			_aShimaa _eCataloger
942			_2ddc _cTH
999			_c62835 _d62835